arrow
D

Daniel Wright

university of oxford
H指数:44
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial

乌干达健康成人中ChAdOx1 RVF疫苗预防裂谷发热的安全性、耐受性和免疫原性: 一项单中心、单盲、随机、安慰剂对照、剂量递增、1期试验

2025-11-110
OAAI
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)

人类季节性冠状病毒免疫力的年龄差异以及ChAdOx1 nCoV-19(AZD1222)的免疫原性

2025-07-160
OA
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK : a dose-escalation, randomised, controlled, phase 1 trial
2024-08-018
OAAI
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
2023-08-0110
OAAI
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

两剂ChAdOx1 nCov-19 (AZD1222) 后免疫反应的持续性: 两项随机对照试验的1年随访

2023-02-028
OAAI
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
2021-07-2615
OAAI
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

肯尼亚第一波新型冠状病毒肺炎流行期间SARS-CoV-2血清阳性率的时间趋势

2021-06-2528
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (vol 27, pg 270, 2021)
2021-05-215
OAAI
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

自我扩增RNA和腺病毒COVID疫苗的异源疫苗接种方案在小鼠中诱导强大的免疫反应

2021-05-1795
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (vol 27, pg 279, 2021)
2021-05-066
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020-12-17454
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020-12-17233
OAAI